Towards Pharma 4.0 in clinical trials: A future-orientated perspective.

Pharma 4.0, a technology ecosystem in drug development analogous to Industry 4.0 in healthcare, is transforming the traditional approach to drug discovery and development, aligning product quality with less time to market, and creating intelligent stakeholder networks through effective collaborations. The wide range of potential Pharma 4.0 networks have produced several conceptualizations, which have led to a lack of clarity and definition. The main emphasis of this paper is on the clinical trial stage of drug development in the Pharma 4.0 era. It highlights the merged computerized technologies that are currently used in clinical research, and proposes a framework for integrating Pharma 4.0 technologies. The impact of and barriers to employing the proposed framework are discussed, highlighting its potential and some future research applications.

Cyber-physical-based PAT (CPbPAT) framework for Pharma 4.0.

Industry 4.0 aims to integrate manufacturing operations into a seamless digital whole by incorporating flexibility, agility, re-configurability, and sustainability. The result of this integration is a "smart factory" that is more lean, agile, and flexible in operations. There are valid reasons, and perhaps requirements, for pharmaceutical industries to embrace smart factory and to "borrow" the concept of Industry 4.0 to give rise to "Pharma 4.0" (i.e., the pharmaceutical version of Industry 4.0). This paper proposes a cyber-physical-based PAT framework called CPbPAT for implementing smart manufacturing systems in the pharmaceutical industry. The framework has been developed using an agent-based system and is presented by a standard system modeling language called the Unified Modeling Language (UML). The pharmaceutical manufacturing system shown in "Quality by Design for ANDAs" is used as a case study to illustrate the application of the proposed framework.